Longboard Pharmaceuticals, Inc. ( (LBPH) ) has released its Q3 earnings. Here is a breakdown of the information Longboard Pharmaceuticals, Inc.

Begin your TipRanks Premium journey today. Longboard Pharmaceuticals (LBPH) Company Description: Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel ...

Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and ...

Longboard Pharmaceuticals (NASDAQ:LBPH) disclosed that the HSR waiting period for its planned $2.6 billion sale to Lundbeck ...

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...

Avid was founded in 2002 as a spinout of biopharmaceutical company Peregrine Pharmaceuticals. “Since our founding, Avid ...

Avid was founded in 2002 as a spinout of biopharmaceutical company Peregrine Pharmaceuticals. “Since our founding, Avid ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

EMERYVILLE, Calif., November 07, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024. EMERYVILLE ...

Lundbeck, a biopharmaceutical company based in Denmark, has announced the acquisition of Longboard Pharmaceuticals in a strategic deal valued at approximately USD 2.6 billion. The acquisition is ...